Company Overview of Zenith Epigenetics Corp.
Key Executives for Zenith Epigenetics Corp.
Chairman, Chief Executive Officer and President
Chief Financial Officer and Secretary
Senior Vice President of Operations
Compensation as of Fiscal Year 2017.
Zenith Epigenetics Corp. Key Developments
Zenith Epigenetics Corp. Presents at BIO International Conference 2017, Jun-20-2017 03:30 PM
Jun 5 17
Zenith Epigenetics Corp. Presents at BIO International Conference 2017, Jun-20-2017 03:30 PM. Venue: San Diego Convention Center, San Diego, CA 2865, United States. Speakers: Donald J. McCaffrey, Chairman, Chief Executive Officer and President.
Zenith Epigenetics Corp. Presents at 19th Annual BIO CEO & Investor Conference, Feb-14-2017 11:15 AM
Jan 3 17
Zenith Epigenetics Corp. Presents at 19th Annual BIO CEO & Investor Conference, Feb-14-2017 11:15 AM. Venue: The Waldorf Astoria New York, 301 Park Avenue, New York, NY 10022, United States. Speakers: Donald J. McCaffrey, Chairman, Chief Executive Officer and President.
Zenith Epigenetics Ltd. Announces Initiation of Phase 1b Clinical Combination Trial for ZEN-3694
Dec 14 16
Zenith Epigenetics Ltd. has initiated a Phase 1b clinical trial in metastatic Castration Resistant Prostate Cancer (mCRPC) patients, dosing ZEN-3694 in combination with enzalutamide. In this Phase 1b trial, Zenith Epigenetics will be evaluating the safety, pharmacokinetics, and efficacy of ZEN-3694 in combination with, enzalutamide (Xtandi) in mCRPC patients that have progressed on first-line standard-of-care anti-androgen therapy. The trial will encompass a dose escalation phase and an expansion phase, designed to potentially show early proof-of-concept. The trial also includes a broad translational program, measuring target modulation as well as evaluating potential pharmacodynamic biomarkers for identifying patients who may benefit the most from the combination treatment. Zenith Epigenetics continues to advance its single agent Phase 1 clinical trial with ZEN-3694, working with prominent clinical investigators and the Prostate Cancer Clinical Trial Consortium (PCCTC) who collectively have been instrumental in developing leading drugs for the treatment of mCRPC, including enzalutamide and abiraterone (Xtandi and Zytiga respectively). Zenith Epigenetics has also developed strong pre-clinical rationale for developing ZEN-3694 in other oncology indications which may be explored in future clinical programs.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries